Last reviewed · How we verify
Pemetrexed + Cisplatin /Carboplatin
Pemetrexed is a folate antagonist that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to cell death in rapidly dividing cancer cells. Cisplatin and Carboplatin are platinum-based chemotherapeutic agents that induce DNA crosslinks, causing cell death.
Pemetrexed is a folate antagonist that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to cell death in rapidly dividing cancer cells. Cisplatin and Carboplatin are platinum-based chemotherapeutic agents that induce DNA crosslinks, causing cell death. Used for Non-small cell lung cancer, Mesothelioma.
At a glance
| Generic name | Pemetrexed + Cisplatin /Carboplatin |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | Antineoplastic agent |
| Target | Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pemetrexed's mechanism of action involves the inhibition of key enzymes involved in DNA synthesis, leading to the depletion of thymidine and the induction of apoptosis in cancer cells. Cisplatin and Carboplatin work by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.
Approved indications
- Non-small cell lung cancer
- Mesothelioma
Common side effects
- Nausea
- Vomiting
- Anemia
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: